{
    "clinical_study": {
        "@rank": "57112", 
        "acronym": "COOOL", 
        "arm_group": {
            "arm_group_label": "Oxytocin", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive intranasal oxytocin 40 International Units (IU) twice daily for two weeks"
        }, 
        "brief_summary": {
            "textblock": "This will be a pilot feasibility study assessing the tolerability of chronic administration\n      of intranasal oxytocin to patients receiving methadone at an opioid replacement clinic who\n      are actively using cocaine."
        }, 
        "brief_title": "Cocaine Opioid Oxytocin Option - Limited", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Opioid Use Disorder", 
            "Cocaine Use Disorder"
        ], 
        "condition_browse": {
            "mesh_term": "Substance-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Enrolled as a patient in the San Francisco General Hospital Opioid Treatment\n             Outpatient Program\n\n          -  Stable dose of methadone for at least the past two weeks\n\n          -  At least one routine urine toxicology screen positive for cocaine in the past month\n\n        Exclusion Criteria:\n\n          -  Positive urine pregnancy test\n\n          -  Use of illicit drugs in the past month (with the exception of cocaine)\n\n          -  Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major\n             depressive disorder with suicidal thoughts or actions\n\n          -  History of psychotic or moderate-severe alcohol use disorder as defined by DSM-V\n             criteria\n\n          -  Severe neuropsychological disorder, brain trauma, epilepsy\n\n          -  Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol\n             hemihydrate)\n\n          -  Nasal obstruction, discharge, or bleeding\n\n          -  Habitually drinks large volumes of water\n\n          -  Taking antipsychotics or mood stabilizers, testosterone or estrogen/progesterone\n             supplement, or serotonin-1a receptor agonists/antagonists"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028533", 
            "org_study_id": "UCSF-COOOL1"
        }, 
        "intervention": {
            "arm_group_label": "Oxytocin", 
            "intervention_name": "Oxytocin", 
            "intervention_type": "Drug", 
            "other_name": "Syntocinon"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Oxytocin", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "addiction", 
            "oxytocin", 
            "tolerability"
        ], 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94110"
                }, 
                "name": "San Francisco General Hospital Opiate Treatment Outpatient Program"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tolerability and Feasibility Study of Chronic Intranasal Oxytocin as an Adjunct to Methadone Maintenance Treatment in Patients With Co-occuring Opioid Use Disorder and Cocaine Use: A Two Week Pilot Study", 
        "overall_contact": {
            "email": "christopher.stauffer@ucsf.edu", 
            "last_name": "Christopher S Stauffer, MD", 
            "phone": "415-476-7247"
        }, 
        "overall_contact_backup": {
            "last_name": "Olivia Lam", 
            "phone": "415-221-4810", 
            "phone_ext": "4117"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Christopher S Stauffer, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Joshua Woolley, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with non-serious and serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028533"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Christopher Stauffer", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}